Boston Scientific’s corporate headquarters in the US. Credit: Boston Scientific Corporation.

Boston Scientific has closed an investment and signed an acquisition option agreement, focusing on heart valve repair with Millipede.

Under the agreement, Boston Scientific has bought certain outstanding and newly issued shares of Millipede for a total consideration of $90m.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The terms further provide Boston Scientific with an option to acquire the remaining shares of Millipede for an additional $325m at any time before the completion of the first clinical trial of the firm’s IRIS Transcatheter Annuloplasty Ring System.

Upon completion of this study, Millipede exercises the option to compel Boston Scientific to purchase its remaining shares. The option period of both the companies expires by the end of 2019.

Millipede is further eligible for a $125m payment upon achieving a commercial milestone.

“Restoring mitral annular dimensions via a transcatheter mitral annuloplasty ring will be a crucial component to effective, minimally invasive improvement of mitral valve function.”

Boston Scientific executive vice-president and global chief medical officer Ian Meredith said: “Intervening with the least invasive approach at earlier stages of severe mitral regurgitation has the greatest opportunity to alter the natural history of the disease and the progression to heart failure.

“We believe that restoring mitral annular dimensions via a transcatheter mitral annuloplasty ring will be a crucial component to effective, minimally invasive improvement of mitral valve function for appropriately indicated patients.”

Developed to treat severe mitral regurgitation (MR), the Millipede IRIS annuloplasty ring is delivered through a transcatheter-transseptal delivery system to repair and minimise the size of the dilated mitral annulus.

Millipede board chairman Joe Cunningham said: “We saw an opportunity to bring the gold-standard surgical approach to repairing the mitral valve to an underserved population of severe MR patients with transcatheter techniques, and are excited Boston Scientific also sees the unique abilities of the IRIS transcatheter ring.”